MA39838A - Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 - Google Patents

Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4

Info

Publication number: MA39838A
Authority: MA; Morocco
Prior art keywords: heteraryl; merged; bicyclic compounds; aryl bicyclic; irak4 inhibitors
Prior art date: 2014-04-04

Application number

MA039838A

Other languages

English (en)

Other versions

MA39838B1 (fr

Inventor

David Randolph Anderson

Mark Edward Bunnage

Kevin Joseph Curran

Christoph Martin Dehnhardt

Lori Krim Gavrin

Joel Adam Goldberg

Seungil Han

David Hepworth

Horng-Chih Huang

Arthur Lee

Katherine Lin Lee

Frank Eldridge Lovering

Michael Dennis Lowe

John Paul Mathias

Nikolaos Papaioannou

Akshay Patny

Betsy Susan Pierce

Eddine Saiah

Joseph Walter Strohbach

John David Trzupek

Richard Vargas

Xiaolun Wang

Stephen Wayne Wright

Christoph Wolfgang Zapf

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-04

Filing date

2015-03-26

Publication date

2017-02-08

2015-03-26 Application filed by Pfizer filed Critical Pfizer

2017-02-08 Publication of MA39838A publication Critical patent/MA39838A/fr

2019-05-31 Publication of MA39838B1 publication Critical patent/MA39838B1/fr

Links

229940127590 IRAK4 inhibitor Drugs 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Communicable Diseases (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

MA39838A 2014-04-04 2015-03-26 Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4 MA39838B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201461975473P	2014-04-04	2014-04-04
PCT/IB2015/052251 WO2015150995A1 (fr)	2014-04-04	2015-03-26	Composés à base d'hétéroaryle ou d'aryle fusionné-bicyclique et leur utilisation comme composés inhibiteurs de l'irak 4
EP15717250.3A EP3126330B1 (fr)	2014-04-04	2015-03-26	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4

Publications (2)

Publication Number	Publication Date
MA39838A true MA39838A (fr)	2017-02-08
MA39838B1 MA39838B1 (fr)	2019-05-31

Family

ID=52988358

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA39838A MA39838B1 (fr)	2014-04-04	2015-03-26	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
MA52856A MA52856B1 (fr)	2014-04-04	2015-03-26	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
MA52856A MA52856B1 (fr)	2014-04-04	2015-03-26	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4

Country Status (46)

Country	Link
US (6)	US9458168B2 (fr)
EP (2)	EP3536685B1 (fr)
JP (2)	JP6177456B2 (fr)
KR (1)	KR101901044B1 (fr)
CN (1)	CN106458912B (fr)
AP (1)	AP2016009514A0 (fr)
AR (1)	AR099955A1 (fr)
AU (1)	AU2015242291B2 (fr)
BR (1)	BR112016023117B1 (fr)
CA (1)	CA2944475C (fr)
CL (1)	CL2016002524A1 (fr)
CR (1)	CR20160456A (fr)
CU (1)	CU24406B1 (fr)
CY (2)	CY1121694T1 (fr)
DK (2)	DK3536685T3 (fr)
DO (1)	DOP2016000271A (fr)
EA (1)	EA032559B1 (fr)
EC (1)	ECSP16076566A (fr)
ES (2)	ES2718552T3 (fr)
GE (1)	GEP20186887B (fr)
GT (1)	GT201600215A (fr)
HR (2)	HRP20220362T1 (fr)
HU (2)	HUE057876T2 (fr)
IL (1)	IL248158B (fr)
LT (2)	LT3126330T (fr)
MA (2)	MA39838B1 (fr)
MD (1)	MD4779B1 (fr)
ME (1)	ME03599B (fr)
MX (1)	MX2016013052A (fr)
MY (1)	MY192521A (fr)
NI (1)	NI201600152A (fr)
NZ (1)	NZ724578A (fr)
PE (1)	PE20161251A1 (fr)
PH (1)	PH12016501972B1 (fr)
PL (2)	PL3126330T3 (fr)
PT (2)	PT3536685T (fr)
RS (2)	RS63024B1 (fr)
SG (1)	SG11201608110WA (fr)
SI (2)	SI3536685T1 (fr)
SV (1)	SV2016005295A (fr)
TR (1)	TR201904658T4 (fr)
TW (3)	TWI580678B (fr)
UA (1)	UA121467C2 (fr)
UY (1)	UY36056A (fr)
WO (1)	WO2015150995A1 (fr)
ZA (1)	ZA201606550B (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI3321359T1 (sl)	2005-04-11	2021-07-30	Horizon Pharma Rheumatology Llc	Variantne oblike urat oksidaze in uporaba le-teh
HUP1200205A3 (en)	2009-06-25	2012-09-28	Savient Pharmaceuticals	Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy
CN108864151A (zh)	2010-11-19	2018-11-23	利亘制药公司	杂环胺及其用途
GB201311888D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201311891D0 (en)	2013-07-03	2013-08-14	Glaxosmithkline Ip Dev Ltd	Novel compound
JP6554116B2 (ja)	2014-04-04	2019-07-31	ハー・ルンドベック・アクチエゼルスカベット	Ｐｄｅ１阻害剤としてのハロゲン化キナゾリン−ｔｈｆ−アミン
MA39838B1 (fr) *	2014-04-04	2019-05-31	Pfizer	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
CA2995153A1 (fr)	2015-08-13	2017-02-16	Pfizer Inc.	Composes aryle ou heteroaryle condenses bicycliques
MX2018002402A (es)	2015-08-27	2018-04-11	Pfizer	Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
WO2018026877A1 (fr)	2016-08-05	2018-02-08	Calitor Sciences, Llc	Méthode de préparation de composés de quinoléine-4-ol substitués
US11254667B2 (en)	2016-08-17	2022-02-22	Children's Hospital Medical Center	Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
US11542261B2 (en)	2016-08-17	2023-01-03	Children's Hospital Medical Center	Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors
CN117017985A (zh) *	2016-10-13	2023-11-10	特拉维尔治疗公司	用于治疗肾脏疾病或病症的联苯磺酰胺化合物
KR20180066296A (ko) *	2016-12-07	2018-06-19	서울대학교산학협력단	토파시티닙을 포함하는 고염증 증상의 예방 또는 치료용 약학적 조성물 및 토파시티닙을 포함하는 고염증 증상의 예방 또는 개선용 건강기능식품 조성물
JOP20180011A1 (ar)	2017-02-16	2019-01-30	Gilead Sciences Inc	مشتقات بيرولو [1، 2-b]بيريدازين
PE20191817A1 (es)	2017-05-11	2019-12-27	Bristol Myers Squibb Co	Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
CN107021960B (zh) *	2017-06-10	2018-07-31	上海普康药业有限公司	一种治疗恶性肿瘤的药物
GB201712282D0 (en) *	2017-07-31	2017-09-13	Nodthera Ltd	Selective inhibitors of NLRP3 inflammasome
JP7366031B2 (ja)	2017-09-22	2023-10-20	カイメラセラピューティクス，インコーポレイテッド	タンパク質分解剤およびそれらの使用
WO2019060693A1 (fr)	2017-09-22	2019-03-28	Kymera Therapeutics, Inc.	Ligands crbn et utilisations de ces derniers
AU2018351651B2 (en)	2017-10-20	2023-01-05	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor M4
EP3704104A4 (fr) *	2017-10-30	2021-07-28	Synblia Therapeutics, Inc.	Inhibiteurs d'irak4 et leurs utilisations
WO2019089676A1 (fr) *	2017-10-31	2019-05-09	Vanderbilt University	Antagonistes du récepteur muscarinique m4 à l'acétylcholine
US11065231B2 (en)	2017-11-17	2021-07-20	Arvinas Operations, Inc.	Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
WO2019111218A1 (fr)	2017-12-08	2019-06-13	Cadila Healthcare Limited	Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs d'irak4
JP2021508703A (ja)	2017-12-26	2021-03-11	カイメラセラピューティクス，インコーポレイテッド	Ｉｒａｋ分解剤およびそれらの使用
EP3737666A4 (fr)	2018-01-12	2022-01-05	Kymera Therapeutics, Inc.	Agents de dégradation de protéines et utilisations associées
WO2019140387A1 (fr)	2018-01-12	2019-07-18	Kymera Therapeutics, Inc.	Ligands crbn et leurs utilisations
CN111971278B (zh) *	2018-01-31	2023-08-11	默克专利有限公司	用作irak抑制剂的喹啉化合物及其用途
US11414406B2 (en)	2018-02-02	2022-08-16	Vanderbilt University	Antagonists of the muscarinic acetylcholine receptor M4
CR20200347A (es)	2018-02-13	2020-09-23	Gilead Sciences Inc	Inhibidores pd-1/pd-l1
EP3752504A4 (fr) *	2018-02-14	2021-06-09	Dana Farber Cancer Institute, Inc.	Composés dégradant les irak et utilisations de ces derniers
CN108299397B (zh) *	2018-03-21	2019-01-29	佳木斯大学附属第一医院	一种用于降血压的活性药物及其制备方法
CN112041311B (zh)	2018-04-19	2023-10-03	吉利德科学公司	Pd-1/pd-l1抑制剂
EP3810144A4 (fr) *	2018-06-04	2022-08-17	Chemistryrx	Compositions topiques pour stimuler la pousse des cheveux
US11292792B2 (en)	2018-07-06	2022-04-05	Kymera Therapeutics, Inc.	Tricyclic CRBN ligands and uses thereof
TWI721483B (zh)	2018-07-13	2021-03-11	美商基利科學股份有限公司	吡咯并[1,2-b]嗒𠯤衍生物
CN109147870A (zh) *	2018-07-26	2019-01-04	刘滨	基于条件随机场的固有无序蛋白质的识别方法
CA3105558C (fr)	2018-08-13	2023-09-26	Gilead Sciences, Inc.	Derives de pyrrolo [1,2-b] pyridazine en tant qu'inhibiteurs d'irak4
EP3837012A1 (fr)	2018-08-13	2021-06-23	Gilead Sciences, Inc.	Dérivés de pyrrolo [1,2-b] pyridazine en tant qu'inhibiteurs d'irak4
TWI727392B (zh)	2018-08-13	2021-05-11	美商基利科學股份有限公司	噻二唑irak4抑制劑
KR20210111252A (ko)	2018-11-30	2021-09-10	카이메라 쎄라퓨틱스 인코포레이티드	Irak 분해제 및 이의 용도
DE102018221954A1 (de) *	2018-12-17	2020-06-18	Robert Bosch Gmbh	Recheneinrichtung und Verfahren zum Betreiben einer Recheneinrichtung
US20200237879A1 (en) *	2019-01-30	2020-07-30	Horizon Pharma Rheumatology Llc	Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
CN111662295B (zh) *	2019-03-05	2021-09-10	珠海宇繁生物科技有限责任公司	一种irak4激酶抑制剂及其制备方法
KR102289661B1 (ko) *	2019-05-15	2021-08-17	가톨릭대학교 산학협력단	요산분해효소를 과발현하는 줄기세포를 유효성분으로 포함하는 통풍의 예방 또는 치료용 조성물
WO2021026181A1 (fr) *	2019-08-06	2021-02-11	Bristol-Myers Squibb Company	Composés hétérocycliques bicycliques utilisés en tant qu'inhibiteurs d'irak4
CN112679472A (zh) *	2019-10-17	2021-04-20	北京桦冠医药科技有限公司	具有irak4抑制剂活性的异喹啉类化合物
WO2021094953A1 (fr)	2019-11-14	2021-05-20	Pfizer Inc.	Combinaisons de 1-(((2s,3s,4s)-3-éthyl-4-fluoro-5-oxopyrrolidin-2-yl)méthoxy)-7-méthoxyisoquinoléine-6-carboxamide et formes pharmaceutiques orales
US20210154292A1 (en) *	2019-11-21	2021-05-27	Chemocentryx, Inc.	Compositions and Methods for Treating CCR9-Mediated Diseases using CCR9 Inhibitor and Anti-TNF-Alpha Blocking Antibodies
EP4076524A4 (fr)	2019-12-17	2023-11-29	Kymera Therapeutics, Inc.	Agents de dégradation d'irak et leurs utilisations
TW202136251A (zh)	2019-12-17	2021-10-01	美商凱麥拉醫療公司	Irak降解劑及其用途
CA3166527A1 (fr) *	2020-01-29	2021-08-05	Charbel MOUSSA	Compositions et methodes de traitement de troubles neurodegeneratifs, neurodeveloppementaux, myodegeneratifs et du stockage lysosomal
US11618751B1 (en)	2022-03-25	2023-04-04	Ventus Therapeutics U.S., Inc.	Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
CA3177852A1 (fr)	2020-04-04	2021-10-07	Pfizer Inc.	Procedes de traitement de la maladie a coronavirus 2019
TW202210483A (zh)	2020-06-03	2022-03-16	美商凱麥拉醫療公司	Irak降解劑之結晶型
JP7422242B2 (ja)	2020-09-30	2024-01-25	旭化成ファーマ株式会社	マクロサイクル化合物
JP7433463B2 (ja)	2020-09-30	2024-02-19	旭化成ファーマ株式会社	ピリミジン含有含窒素二環化合物
US11866405B2 (en)	2020-12-10	2024-01-09	Astrazeneca Ab	Substituted indazoles as IRAK4 inhibitors
AU2022378630A1 (en) *	2021-10-29	2024-05-09	Kymera Therapeutics, Inc.	Irak4 degraders and synthesis thereof
KR20240051921A (ko)	2022-02-14	2024-04-22	아스트라제네카 아베	Irak4 억제제
US20230312568A1 (en)	2022-03-31	2023-10-05	Rigel Pharmaceuticals, Inc.	Tricyclic irak inhibitors
WO2023227703A1 (fr)	2022-05-26	2023-11-30	Astrazeneca Ab	Formes solides d'hétérocyclylamides utilisées comme inhibiteurs de l'irak 4
US20230391748A1 (en) *	2022-06-01	2023-12-07	Rigel Pharmaceuticals, Inc.	Bicyclic inhibitors of irak

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3673238A (en) *	1970-02-10	1972-06-27	Usv Pharma Corp	2-naphthoic acid derivatives
DE3065190D1 (en)	1979-11-05	1983-11-10	Beecham Group Plc	Enzyme derivatives, and their preparation
DE3882894T2 (de)	1987-10-20	1994-03-17	Mitsui Toatsu Chemicals	1,2-Naphtalocyanine, Infrarotabsorber und sie verwendende Aufzeichnungsmaterialien.
US4861795A (en) *	1988-06-23	1989-08-29	Rorer Pharmaceutical Corporation	Treatment of conditions requiring enhanced oxygen availability to mammalian tissues
JP2671059B2 (ja) *	1990-11-30	1997-10-29	富士レビオ株式会社	ナフトエ酸誘導体
JPH05148222A (ja)	1991-11-29	1993-06-15	Fujirebio Inc	ナフトエ酸誘導体
US5837689A (en) *	1993-06-16	1998-11-17	Glycomed Incorporated	Sialyl lewis-x mimetics containing naphthyl backbones
AU686691B2 (en)	1994-01-12	1998-02-12	F. Hoffmann-La Roche Ag	Novel azepanes and homologs thereof
US5612359A (en)	1994-08-26	1997-03-18	Bristol-Myers Squibb Company	Substituted biphenyl isoxazole sulfonamides
CA2174583A1 (fr)	1995-05-05	1996-11-06	Alexander Chucholowski	Esters d'acide sulfurique et d'itols
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
TW536540B (en)	1997-01-30	2003-06-11	Bristol Myers Squibb Co	Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
DE69940063D1 (de)	1998-07-06	2009-01-22	Bristol Myers Squibb Co	Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
BR0012157A (pt) *	1999-07-07	2002-04-02	Astrazeneca Uk Ltd	Derivado de quinazolina, derivado de pirimidina, processo para a preparação de um derivado de quinazolina, composição farmacêutica, uso de um derivado de quinazolina, e, método para a prevenção ou tratamento de doenças ou condições médicas pela célula t um em animal de sangue quente em necessidade de tal tratamento
MY125533A (en)	1999-12-06	2006-08-30	Bristol Myers Squibb Co	Heterocyclic dihydropyrimidine compounds
EP1415987B1 (fr) *	2000-10-20	2007-02-28	Eisai R&D Management Co., Ltd.	Composes heteroaromatiques azotes pour le traitement des maladies de cancer
AU2003248354A1 (en)	2002-02-27	2003-09-09	Pfizer Products Inc.	Acc inhibitors
EP1724268A4 (fr) *	2004-02-20	2010-04-21	Kirin Pharma Kk	Compose ayant une activite d'inhibition du tgf-beta et composition pharmaceutique contenant celui-ci
ATE437870T1 (de)	2004-05-12	2009-08-15	Pfizer Prod Inc	Prolinderivate und deren verwendung als dipeptidylpeptidase-iv-inhibitoren
MX2007016070A (es)	2005-07-07	2008-03-10	Abbott Lab	Promotores de apoptosis.
US7572809B2 (en)	2005-12-19	2009-08-11	Hoffmann-La Roche Inc.	Isoquinoline aminopyrazole derivatives
NL2000581C2 (nl)	2006-04-20	2008-01-03	Pfizer Prod Inc	Aangecondenseerde fenylamidoheterocyclische verbindingen.
MX2009005604A (es)	2006-11-29	2009-06-08	Pfizer Prod Inc	Inhibidores espiro cetona de acetil-coa carboxilasa.
EP2647376A1 (fr)	2007-01-22	2013-10-09	Gtx, Inc.	Agents de liaison de récepteur nucléaire
US9623021B2 (en)	2007-01-22	2017-04-18	Gtx, Inc.	Nuclear receptor binding agents
WO2008103354A2 (fr)	2007-02-20	2008-08-28	Cropsolution, Inc.	Modulateurs de l'acétyl-coenzyme a carboxylase et procédés d'utilisation de ceux-ci
WO2009000085A1 (fr)	2007-06-27	2008-12-31	Painceptor Pharma Corporation	Dérivés de quinoline et de quinazoline utiles comme modulateurs des canaux ioniques
US20090036425A1 (en)	2007-08-02	2009-02-05	Pfizer Inc	Substituted bicyclolactam compounds
CN101245022A (zh) *	2008-03-21	2008-08-20	东华大学	3,5-双(2,4-二氨基苯氧基)-2-萘甲酸的制备方法
ES2545231T3 (es)	2008-05-28	2015-09-09	Pfizer Inc.	Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
US20110009443A1 (en)	2008-05-28	2011-01-13	Kevin Daniel Freeman-Cook	Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
DE102008027574A1 (de)	2008-06-10	2009-12-17	Merck Patent Gmbh	Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
CN101353307A (zh) *	2008-07-25	2009-01-28	东华大学	3,5-双(2,6-二硝基-4-三氟甲基苯氧基)-2-萘甲酸的制备方法
EP2318370A1 (fr)	2008-07-29	2011-05-11	Pfizer Inc.	Hétéroaryles fluorés
PE20110288A1 (es)	2008-08-28	2011-05-26	Pfizer	Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
WO2010086820A1 (fr)	2009-02-02	2010-08-05	Pfizer Inc.	Dérivés de 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazépin-6(5h)-yl)phényle
BRPI1013246B1 (pt)	2009-03-11	2019-10-01	Pfizer, Inc.	Derivados de benzofuranila, suas composições farmacêuticas e seus usos
CA2754685A1 (fr)	2009-03-11	2010-09-16	Pfizer Inc.	Indazole amides substitues
EP2408780A2 (fr)	2009-03-20	2012-01-25	Pfizer Inc.	3-oxa-7-azabicycloý3,3.1¨nonanes
EP2427448A1 (fr)	2009-05-08	2012-03-14	Pfizer Inc.	Modulateurs du gpr119
WO2010128425A1 (fr)	2009-05-08	2010-11-11	Pfizer Inc.	Modulateurs de gpr119
PE20120399A1 (es)	2009-06-05	2012-04-24	Pfizer	Derivados del l-(piperidin-4-il)-pirazol como moduladores de gpr 119
WO2011005611A1 (fr)	2009-07-09	2011-01-13	Merck Sharp & Dohme Corp.	Agonistes du récepteur de la neuromédine u et leurs utilisations
WO2011153553A2 (fr)	2010-06-04	2011-12-08	The Regents Of The University Of California	Méthodes et compositions pour l'inhibition de kinases
WO2011159781A2 (fr)	2010-06-17	2011-12-22	Senomyx, Inc.	Modulateurs de goût amer
CN103827090B (zh)	2011-07-26	2016-04-20	勃林格殷格翰国际有限公司	取代的喹啉及其作为药物的用途
WO2013142390A1 (fr)	2012-03-21	2013-09-26	Gtx, Inc.	Inhibiteurs de la sous-famille 1c3 d'aldo-céto réductase (akr1c3)
WO2014039820A1 (fr)	2012-09-07	2014-03-13	Gtx, Inc.	Inhibiteurs de la sous-famille 1c3 de l'aldo-céto réductase (akr1c3)
MX2016001427A (es)	2013-07-31	2016-08-03	Gilead Sciences Inc	Inhibidores de syk.
MA39838B1 (fr)	2014-04-04	2019-05-31	Pfizer	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
MX2018002402A (es) *	2015-08-27	2018-04-11	Pfizer	Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).

2015
- 2015-03-26 MA MA39838A patent/MA39838B1/fr unknown
- 2015-03-26 RS RS20220257A patent/RS63024B1/sr unknown
- 2015-03-26 LT LTEP15717250.3T patent/LT3126330T/lt unknown
- 2015-03-26 TR TR2019/04658T patent/TR201904658T4/tr unknown
- 2015-03-26 EP EP19157789.9A patent/EP3536685B1/fr active Active
- 2015-03-26 BR BR112016023117-1A patent/BR112016023117B1/pt active IP Right Grant
- 2015-03-26 SI SI201531825T patent/SI3536685T1/sl unknown
- 2015-03-26 DK DK19157789.9T patent/DK3536685T3/da active
- 2015-03-26 HR HRP20220362TT patent/HRP20220362T1/hr unknown
- 2015-03-26 EP EP15717250.3A patent/EP3126330B1/fr active Active
- 2015-03-26 NZ NZ724578A patent/NZ724578A/en unknown
- 2015-03-26 AU AU2015242291A patent/AU2015242291B2/en active Active
- 2015-03-26 PT PT191577899T patent/PT3536685T/pt unknown
- 2015-03-26 EA EA201600622A patent/EA032559B1/ru unknown
- 2015-03-26 CU CU2016000149A patent/CU24406B1/es unknown
- 2015-03-26 MY MYPI2016703626A patent/MY192521A/en unknown
- 2015-03-26 AP AP2016009514A patent/AP2016009514A0/en unknown
- 2015-03-26 CN CN201580029784.3A patent/CN106458912B/zh active Active
- 2015-03-26 MD MDA20160106A patent/MD4779B1/ro not_active IP Right Cessation
- 2015-03-26 LT LTEP19157789.9T patent/LT3536685T/lt unknown
- 2015-03-26 UA UAA201610113A patent/UA121467C2/uk unknown
- 2015-03-26 PL PL15717250T patent/PL3126330T3/pl unknown
- 2015-03-26 ES ES15717250T patent/ES2718552T3/es active Active
- 2015-03-26 CA CA2944475A patent/CA2944475C/fr active Active
- 2015-03-26 MA MA52856A patent/MA52856B1/fr unknown
- 2015-03-26 HU HUE19157789A patent/HUE057876T2/hu unknown
- 2015-03-26 CR CR20160456A patent/CR20160456A/es unknown
- 2015-03-26 ME MEP-2019-113A patent/ME03599B/fr unknown
- 2015-03-26 PE PE2016001905A patent/PE20161251A1/es unknown
- 2015-03-26 WO PCT/IB2015/052251 patent/WO2015150995A1/fr active Application Filing
- 2015-03-26 PL PL19157789T patent/PL3536685T3/pl unknown
- 2015-03-26 KR KR1020167030630A patent/KR101901044B1/ko active IP Right Grant
- 2015-03-26 ES ES19157789T patent/ES2910128T3/es active Active
- 2015-03-26 SG SG11201608110WA patent/SG11201608110WA/en unknown
- 2015-03-26 PT PT15717250T patent/PT3126330T/pt unknown
- 2015-03-26 RS RS20190450A patent/RS58597B1/sr unknown
- 2015-03-26 MX MX2016013052A patent/MX2016013052A/es active IP Right Grant
- 2015-03-26 JP JP2016560419A patent/JP6177456B2/ja active Active
- 2015-03-26 HU HUE15717250 patent/HUE044180T2/hu unknown
- 2015-03-26 DK DK15717250.3T patent/DK3126330T3/en active
- 2015-03-26 GE GEAP201514288A patent/GEP20186887B/en unknown
- 2015-03-26 SI SI201530676T patent/SI3126330T1/sl unknown
- 2015-03-27 UY UY0001036056A patent/UY36056A/es not_active Application Discontinuation
- 2015-04-01 AR ARP150101019A patent/AR099955A1/es unknown
- 2015-04-02 TW TW105117087A patent/TWI580678B/zh active
- 2015-04-02 TW TW106105786A patent/TWI623530B/zh active
- 2015-04-02 TW TW104111016A patent/TWI593683B/zh active
- 2015-04-03 US US14/678,114 patent/US9458168B2/en active Active
2016
- 2016-08-10 US US15/232,892 patent/US9879022B2/en active Active
- 2016-09-22 ZA ZA2016/06550A patent/ZA201606550B/en unknown
- 2016-09-26 EC ECIEPI201676566A patent/ECSP16076566A/es unknown
- 2016-09-29 IL IL248158A patent/IL248158B/en active IP Right Grant
- 2016-09-30 SV SV2016005295A patent/SV2016005295A/es unknown
- 2016-10-03 DO DO2016000271A patent/DOP2016000271A/es unknown
- 2016-10-03 NI NI201600152A patent/NI201600152A/es unknown
- 2016-10-04 PH PH12016501972A patent/PH12016501972B1/en unknown
- 2016-10-04 GT GT201600215A patent/GT201600215A/es unknown
- 2016-10-04 CL CL2016002524A patent/CL2016002524A1/es unknown
2017
- 2017-07-11 JP JP2017135751A patent/JP6492128B2/ja active Active
2018
- 2018-01-05 US US15/862,691 patent/US10329302B2/en active Active
2019
- 2019-03-13 HR HRP20190506TT patent/HRP20190506T1/hr unknown
- 2019-04-12 CY CY20191100413T patent/CY1121694T1/el unknown
- 2019-05-14 US US16/411,679 patent/US10793579B2/en active Active
2020
- 2020-08-18 US US16/996,117 patent/US11702424B2/en active Active
2022
- 2022-03-31 CY CY20221100251T patent/CY1125110T1/el unknown
2023
- 2023-06-28 US US18/342,977 patent/US20230339960A1/en active Pending

Also Published As

Publication number	Publication date
TW201722931A (zh)	2017-07-01
MD20160106A2 (ro)	2017-03-31
TWI593683B (zh)	2017-08-01
TWI623530B (zh)	2018-05-11
ES2718552T3 (es)	2019-07-02
US20190270751A1 (en)	2019-09-05
RS58597B1 (sr)	2019-05-31
EP3126330B1 (fr)	2019-02-27
BR112016023117A2 (fr)	2017-08-15
LT3536685T (lt)	2022-04-25
EP3536685B1 (fr)	2022-02-16
TW201540707A (zh)	2015-11-01
CR20160456A (es)	2016-12-01
EA201600622A1 (ru)	2017-02-28
ES2910128T3 (es)	2022-05-11
MA39838B1 (fr)	2019-05-31
GT201600215A (es)	2018-10-19
EP3126330A1 (fr)	2017-02-08
DOP2016000271A (es)	2017-04-16
ECSP16076566A (es)	2017-03-31
JP2017512809A (ja)	2017-05-25
BR112016023117B1 (pt)	2023-02-07
US9879022B2 (en)	2018-01-30
TW201630903A (zh)	2016-09-01
US11702424B2 (en)	2023-07-18
MD4779B1 (ro)	2021-12-31
PT3126330T (pt)	2019-04-29
NZ724578A (en)	2019-05-31
PL3126330T3 (pl)	2019-09-30
ME03599B (fr)	2020-07-20
LT3126330T (lt)	2019-04-25
WO2015150995A1 (fr)	2015-10-08
AU2015242291A1 (en)	2016-10-13
MA52856A (fr)	2021-04-21
EP3536685A1 (fr)	2019-09-11
US9458168B2 (en)	2016-10-04
GEP20186887B (en)	2018-08-27
MX2016013052A (es)	2017-01-09
CN106458912B (zh)	2020-10-27
PL3536685T3 (pl)	2022-05-16
CY1121694T1 (el)	2020-07-31
CN106458912A (zh)	2017-02-22
UA121467C2 (uk)	2020-06-10
NI201600152A (es)	2016-11-18
EA032559B1 (ru)	2019-06-28
TR201904658T4 (tr)	2019-04-22
US10793579B2 (en)	2020-10-06
SV2016005295A (es)	2017-03-28
TWI580678B (zh)	2017-05-01
US20180127432A1 (en)	2018-05-10
RS63024B1 (sr)	2022-04-29
KR20160135363A (ko)	2016-11-25
ZA201606550B (en)	2018-05-30
US20160347760A1 (en)	2016-12-01
US10329302B2 (en)	2019-06-25
US20200377511A1 (en)	2020-12-03
HRP20190506T1 (hr)	2019-05-03
HUE057876T2 (hu)	2022-06-28
SI3536685T1 (sl)	2022-05-31
PH12016501972A1 (en)	2016-12-19
CL2016002524A1 (es)	2017-06-09
KR101901044B1 (ko)	2018-09-20
SG11201608110WA (en)	2016-10-28
MA52856B1 (fr)	2022-03-31
AR099955A1 (es)	2016-08-31
US20150284405A1 (en)	2015-10-08
JP6492128B2 (ja)	2019-03-27
AU2015242291B2 (en)	2018-08-30
CA2944475A1 (fr)	2015-10-08
UY36056A (es)	2015-10-30
HRP20220362T1 (hr)	2022-05-13
CA2944475C (fr)	2018-07-10
JP6177456B2 (ja)	2017-08-09
MY192521A (en)	2022-08-25
CY1125110T1 (el)	2024-02-16
US20230339960A1 (en)	2023-10-26
AP2016009514A0 (en)	2016-10-31
IL248158B (en)	2018-06-28
DK3536685T3 (da)	2022-03-07
JP2017206549A (ja)	2017-11-24
SI3126330T1 (sl)	2019-05-31
CU24406B1 (es)	2019-05-03
HUE044180T2 (hu)	2019-10-28
PE20161251A1 (es)	2016-11-30
DK3126330T3 (en)	2019-04-23
PH12016501972B1 (en)	2016-12-19
PT3536685T (pt)	2022-03-28
CU20160149A7 (es)	2017-04-05

Publication	Publication Date	Title
MA52856A (fr)	2021-04-21	Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
MA44225A (fr)	2018-12-26	Sulfonylurées et composés apparentés et leur utilisation
MA41551A (fr)	2017-12-26	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA47576A (fr)	2020-01-01	Composés inhibiteurs d'oga bicyclique
MA46228A (fr)	2019-07-24	Inhibiteurs bicycliques fusionnés de l'interaction ménine-mll
MA45244A (fr)	2019-04-17	Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA40587A (fr)	2017-06-28	Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak
MA52063A (fr)	2021-05-26	Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu'inhibiteurs de la kallicréine plasmatique
MA40943A (fr)	2017-09-19	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA42919A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
MA40940A (fr)	2017-09-19	Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
MA55748A (fr)	2022-03-02	Procédés de détection d'aav
MA42918A (fr)	2018-08-01	Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
DK3119397T3 (da)	2022-03-28	Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
MA43364A (fr)	2021-04-14	Composés d'alcènes tétrasubstitués et leur utilisation
DK3197883T3 (da)	2020-06-22	Hidtil ukendte forbindelser
MA43169A (fr)	2018-09-12	Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma
MA45613A (fr)	2021-04-28	Composés polycycliques-carbamoylpyridones et leur utilisation pharmaceutique
MA54567A (fr)	2021-10-27	Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
MA45709A (fr)	2019-05-29	Composés diazahétérobicycliques substitués et leur utilisation
MA46963A (fr)	2019-10-09	Méthodes pour déterminer le dosage de céllules car-t
CU20160125A7 (es)	2017-01-10	Inhibidores de diacilglicerol aciltransferasa 2
MA39915B1 (fr)	2019-05-31	Composés de pladiénolide pyridine et leurs procédés d'utilisation
MA40921A (fr)	2017-09-12	Récepteurs antigéniques chimériques anti-cldn et procédés d'utilisation
FR3037236B1 (fr)	2017-05-26	Microcapsules et composition de maquillage ou de tatouage thermochromiques